Experimental cocktail aims to tackle recurrent head and neck cancer

NCT ID NCT05526924

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests a combination of two newer drugs (tislelizumab and pamiparib) plus standard chemotherapy and re-radiation in 30 people whose head and neck cancer has come back. The main goal is to find a safe dose and check for side effects. Participants will be followed for years to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tislelizumab, pamiparib, hydroxyurea, fluorouracil, and radiation
What this could lead to
If it works, this could point toward a new treatment option for people whose head and neck cancer has returned after prior therapy.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, focused on safety and dosing. It is too small and early to know if the combination will be effective or safe for broader use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer head and neck carcinoma Head and Neck Neoplasms head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.